Pims Technology: Towards Optimizing Cancer Treatments

The Aton Group is highlighting its subsidiary Pims Technology, an innovative player in personalized cancer treatment evaluation. Based on PIMS® Q8 technology, developed with Weil Industries, this initiative could transform personalized medicine by rapidly identifying patients who respond to therapies.

Because cancer represents a significant economic burden on healthcare systems, the early identification of therapeutic ineffectiveness could reduce the high costs of unnecessary care. Currently, many therapeutic approaches often prove costly and ineffective due to the lack of appropriate responses in some patients.

Pims Technology plans to deploy its innovative platform in major European cancer centers, marking the beginning of its international expansion. This deployment will enable clinical validation of the technology, which is also protected by several patents, thus ensuring a promising future for personalized medicine.